RNF213 and multiminicore myopathy: Masaki Ito discovered that mutations in RNF213 are associated with the prognosis of surgery for MMD patients, and patients with mutations have a worse prognosis; these discoveries indicate that modulating the immune response elicited by the RNF213 mutation might become a novel therapeutic approach [110].